{"id":"W4405998776","doi":"10.1016/s2213-2600(24)00407-7","title":"Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Respiratory Medicine","topic":"Cystic Fibrosis Research Advances","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; St. Michael's Hospital; Hospital for Sick Children","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health; Deutsche Forschungsgemeinschaft; Vertex Pharmaceuticals; Cystic Fibrosis Trust; Department of Health and Social Care; National Institute for Health and Care Research; Insmed; AstraZeneca; UK Research and Innovation; Cystic Fibrosis Foundation Therapeutics; Great Ormond Street Institute of Child Health; Cystic Fibrosis Canada; European Respiratory Society; American Thoracic Society","keywords":"Ivacaftor; Medicine; Tolerability; Cystic fibrosis; Clinical endpoint; Clinical trial; Adverse effect; Internal medicine; Cystic fibrosis transmembrane conductance regulator","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002716185,0.0007139055,0.002685352,0.0009091548,0.0003879436,0.00009981932,0.001018619,0.0002952493,0.0006242998],"category_scores_gemma":[0.004068295,0.0004467771,0.0004553514,0.002382162,0.000984784,0.0002605223,0.0001652626,0.0008311696,0.00001786424],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003960271,"about_ca_system_score_gemma":0.0006359913,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000596853,"about_ca_topic_score_gemma":0.0002395051,"domain_scores_codex":[0.9937245,0.0008237961,0.001378622,0.001313159,0.001565387,0.001194551],"domain_scores_gemma":[0.9935887,0.002519246,0.0005357746,0.002318941,0.0004179203,0.0006194575],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9242682,0.00274139,0.00452036,0.0001645749,0.003272554,0.00008490326,0.0002169036,0.0001129287,0.02879386,0.0001346816,0.02613565,0.009554039],"study_design_scores_gemma":[0.8204541,0.04166744,0.05663552,0.0009133609,0.009149644,0.00001049411,0.0004118204,0.0008986227,0.00276529,0.0002835207,0.06609762,0.0007125898],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9807999,0.002660234,0.006811392,0.001896694,0.0003747155,0.006143511,0.0007990377,0.0003190755,0.0001954986],"genre_scores_gemma":[0.97795,0.00006038691,0.003772376,0.003095186,0.0119722,0.001002434,0.00138909,0.0001222709,0.0006361072],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1038141,"threshold_uncertainty_score":0.9997984,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05907750964551386,"score_gpt":0.3834071557346643,"score_spread":0.3243296460891505,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}